Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations-Reference-Cited by-同舟云学术

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

Published:2022-01 Issue:1 Volume:25 Page:3-9
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Husereau Don^ORCID,Drummond Michael,Augustovski Federico,de Bekker-Grob Esther,Briggs Andrew H.,Carswell Chris,Caulley Lisa,Chaiyakunapruk Nathorn,Greenberg Dan,Loder Elizabeth,Mauskopf Josephine,Mullins C. Daniel,Petrou Stavros,Pwu Raoh-Fang,Staniszewska Sophie

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference45 articles.

1. Economic evaluation in global perspective: a bibliometric analysis of the recent literature;Pitt;Health Econ,2016

2. The changing face of the cost-utility literature, 1990-2012;Neumann;Value Health,2015

3. Growth and capacity for cost-effectiveness analysis in Africa;Panzer;Health Econ,2020

4. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force;Husereau;Value Health,2013

5. Reporting guidelines of health research studies are frequently used inappropriately;Caulley;J Clin Epidemiol,2020

Cited by 346 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis;Journal of Gynecologic Oncology;2025

2. Cost-effectiveness of pharmacogenetic screening in the management of major depressive disorder in the Spanish Healthcare System;Journal of Affective Disorders;2024-11

3. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China;International Journal of Clinical Pharmacy;2024-09-14

4. Pharmacoeconomic Study of Homeopathic Medicines: A Critical Appraisal of Methods and Conclusions Shows Serious Cause for Concern;Homeopathy;2024-09-09

5. Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost‐effectiveness analysis;Head & Neck;2024-09-08